The first National Disruptive Tech Startup Stars list was unveiled at the recent China (Guangzhou) International Finance Expo, recognizing 44 outstanding startups with groundbreaking potential in core technologies.

Zhongshan-based biopharmaceutical company RabPharma has been named as a "Mercury" Enterprise" for its exceptional innovation achievements and growth potential in the biopharmaceutical sector.

The "Mercury Enterprise" criteria mandate companies to be founded no more than five years ago, have secured over 20 million yuan in cumulative private market investment, and hold a post-money valuation of 100 million yuan to 1 billion yuan after their latest funding round.

RabPharma is a biopharmaceutical firm focused on independent R&D and industrialization of innovative osteoarthritis drugs. It features a bone&joint regenerative medicine R&D team from UC Davis led by a NAM member in the US.